Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2009 / Cilt: 19 - Sayı: 3

Frequency of cytochrome 450 (CYP2C9 and CYP2C19) genetic polimorphisms in patients with colorectal carsinoma

Kolorektal kanserli hastalarda sitokrom P450 (CYP2C9 ve CYP2C19) genetik polimorfizm sıklığı

Pages
134–139
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, asbestos exposure may be considered as a risk factor for colorectal carcinoma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Colorectal cancers are important health problems particularly in developed countries, are multifactorial diseases developing by the effects of both genetic and environmental factors.
📊
Key Findings & Data:In this case-control study, we evaluated the relationship between colorectal carcinoma and gene polymorphizms of CYP2C9 and CYP2C19 which are the members of CYP2C subfamily playing important roles in the metabolism of endogenous and exogenous compounds, and also assessed other possible relations with carcinogens and drugs as well as many other risk factors such as smoking, alcohol, family history of cancer and asbestos exposure.
💡
Conclusion & Impact:Therefore, asbestos exposure may be considered as a risk factor for colorectal carcinoma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Asbest · Sitokrom P-450 enzim sistemi · Çevresel maruziyet

Abstract

Colorectal cancers are important health problems particularly in developed countries, are multifactorial diseases developing by the effects of both genetic and environmental factors. In this case-control study, we evaluated the relationship between colorectal carcinoma and gene polymorphizms of CYP2C9 and CYP2C19 which are the members of CYP2C subfamily playing important roles in the metabolism of endogenous and exogenous compounds, and also assessed other possible relations with carcinogens and drugs as well as many other risk factors such as smoking, alcohol, family history of cancer and asbestos exposure. Eighty-five patients histopathologically diagnosed with colorectal carcinoma admitted to Departments of Medical Oncology and Surgery at Meram Medical Faculty and eighty-five healhty volunteers, who have no family history of cancer, were included in this study. Heterozygote and mutant genotypes of CYP2C9 and CYP2C19 genes were determined by CYP2C9*2, CYP2C9*3 and CYP2C19*2, CYP2C19*3 Mutation Detection Kits by Light Cycler Real Time Polymerase Chain Reaction. Results were statistically compared in these case-control subjects and odds ratios were used. There were no significant differences between patients with colorectal carcinoma and control groups. However, asbestos exposure ratio in patients with colorectal carcinoma was significantly higher (p < 0.05) than control subjects. Therefore, asbestos exposure may be considered as a risk factor for colorectal carcinoma.

Özet

Özellikle gelişmiş ülkelerin önemli sağlık sorunlarından biri olan kolorektal kanserler, genetik ve çevresel faktörlerin katkılarıyla gelişen multifaktöriyel bir hastalıktır. Bu vaka kontrol çalışmasında kolorektal karsinoma ile CYP2C2 alt gurubunun bir üyesi olan endojen ve eksojen maddelerin karsinojenlerin ve ilaçların metabolizmasında önemli rol alan CYP2C9 ve CYP2C19 gen polimorfizmini ve aynı zamanda sigara, alkol, ailede kanser hikayesi, asbestoz maruziyeti gibi risk faktörlerini araştırdık. Çalışmaya ailesinde kanser hikayesi olmayan 85 sağlıklı gönüllü ile Meram Tıp Fakültesi Tıbbi Onkoloji ve Genel Cerrahi kliniklerine başvuran klinik ve histopatolojik olarak çoğunluğu adenokarsinom olan kolorektal kanserli 85 hasta alındı. CYP2C9 ve CYP2C19 genlerinin heterozigot ve mutant genotiplerini belirlemek için CYP2C9*2, CYP2C9*3 ve CYP2C19*2, CYP2C19*3 mutasyon saptama kitleri Light Cycler Real Time Polymerase Chain Reaction ile kullanıldı. Sonuçlar vaka ve kontrol guruplarında istatistiksel olarak karşılaştırıldı ve hesaplanan odds oranları kullanıldı. Kolorektal karsinomdaki risk faktörleri ve CYP2C9*2, CYP2C9*3 ve CYP2C19*2, CYP2C19*3 genlerinin polimorfik genotip sıklıklarının araştırıldığı bu vaka kontrol çalışmasında; kolorektal kanserli hastalar ve kontrol gurubu arasında anlamlı fark saptanamadı. (p > 0.05). Kolorektal kanserli hastalarda beyaz toprağa maruz kalanların oranı anlamlı oranda (p < 0.05) yüksek bulundu ve beyaz toprağın kolorektal kanser için bir risk faktörü olabileceği düşünüldü.

🔖

Cite This Article

BÜYÜKDOĞAN, M., BPRUBAN, M. C., ARTAÇ, M., DEMİREL, S. (2009). Frequency of cytochrome 450 (CYP2C9 and CYP2C19) genetic polimorphisms in patients with colorectal carsinoma. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 19 - Sayı: 3, 134–139. https://ajindex.com/articles/323210

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Fenoglio-Presier CM, Pascal RR, Perzin KH. Tumors of the large and small intestine. AFIP 34: 261-262, 1990
  2. Clinton SK, Giovannucci EL. Nutrition in the Etiology and Prevention of Cancer. Cancer medicine. Holland JF Frei E, Bast RC, Kufe DW Morton DL Weichselbaum R(eds) Williams and Wilkins Baltimore: 465-494, 1997
  3. Özerol E. Cytochrom P 450 containing monooksigenase enzym systems. Journal of Tugut Özal Medical Center. 3: 257-275, 1996
  4. Pchelina O, Sofya N, Anastasiya E, et al. The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity of warfarin. Thromb Res 115: 199-203, 2005
  5. Aynacıoğlu S, Brockmüller J, Bauer S, et al. Frequency of Cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Cli Pharmacol. 48: 409-415, 1999
  6. Stubbins MJ, Harries LW, Smith G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6: 429-439, 1996
  7. Gaedigk A, Casley WL, Tyndale RF, et al. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 79: 841-847, 2001
  8. Wang R, Liu L, Cheng H. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. DMD 24: 786-791, 1995
  9. Landi S, Gemignani F, Moreno V, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphism and risk of colorectal cancer. Pharmacogenet Genomics 15: 535-546, 2005
  10. Le Marchand L. Combined influence of genetic and dietary factors on colorectal cancer in Japanese Americans. JNCI 26: 101-105, 1999
  11. Martinez C, Garcia-Martin E, Ladero JM, et al. High frequency of mutations related to impared CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 57: 47-49, 2001
  12. Pang YS, Wong LP, Lee TC, et al. Genetic polymorphism of cytochrome 2 C19 in P450 healthy Malaysian subjects. Br J Clin. Pharmacol 58: 332-335, 2004
  13. Herman D, Dolzan V, Breskvar K. Genetic polymorphism of cytochrome P450 2 C9 and 2C19 in Slovenian population. Zdrav Vestn 72:347-351, 2003
  14. Scordo MG, Caputi AP, D’Arrigo C, et al. Allel and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 genetic polymorphism in an Italian population. Pharmacol Res 50: 195-200, 2004
  15. Jose R, Chandrasekaran A, Soya SS, et al. CYP2C9 and CYP2C19 genetic polymorphism: frequencies in the South Indian population. Fundam Clin Pharmacol 19